Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content

Provider review

Noom

Behavioral-first program with GLP-1 access — coaching bundled in for adherence-heavy users.

Medically reviewed by Dr. Jane Novak, MD, MPH on July 15, 2026

Rating breakdown

How this provider scored, per dimension

Editorial scores out of 5 — see our scoring rubric for the criteria behind each axis.

Overall
4.0/5
Pricing
3.9/5
Patient experience
4.4/5
Delivery speed
4.1/5
Customer support
4.3/5
Billing clarity
3.7/5

Who's behind this provider

Company snapshot

Founded
2007 (19 years old)
Headquarters
New York, NY
Leadership
Geoff Cook
CEO
Total funding raised
$657M
Prescriber employment
1099 contracted clinicians

Source: noom.com/about + Crunchbase. Last verified 2026-04-12. Funding figures are cumulative disclosed raises; private-company numbers may lag the live cap table by 1 round.

Noom provider review
Noom is a compounded GLP-1 provider operating in 51 U.S. states.Photo: Unsplash
From
$149/mo
Medications
1
States
51
Rating
4.0/5
~2 hr· self-reported

We earn a commission if you sign up through this link. Editorial ranking is independent.

What we liked

  • Coaching + CBT-based habit tools bundled with medication access
  • Well-known app ecosystem for tracking food, weight, activity
  • Ideal for patients who want behavioral support alongside the drug

What gave us pause

  • Coaching adds cost vs pure-medication providers
  • Aggressive marketing / subscription can be hard to cancel
  • GLP-1 add-on is separate from the core Noom Weight subscription

Reader reviews

Verified user experiences. Reviews are moderated before publishing — we strip personal info and reject spam.

No user reviews yet

Be the first to share your experience — consults, shipping, billing, support. The form below takes ~2 minutes.

Share your experience with Noom

Reviews are moderated before publishing. We do not display your email.

Your rating

By submitting, you agree we may publish the rating, title, body, and your name (if provided). Your email is private and used only for verification.

Price drop alert

Get an email the moment this provider's monthly cost drops below your threshold. One email per threshold crossing — no marketing spam.

Ready to try Noom?

From $149.00/mo. Commission-funded, editorially independent.

Get started with Noom
People also ask

Common questions readers ask

How much does Wegovy cost without insurance?
List price runs ~$1,350/mo at retail. NovoCare Pharmacy cash-pay direct from Novo Nordisk is $499/mo for all dose strengths. The Wegovy Savings Offer caps copay at $0-$225/mo for commercially insured patients depending on coverage status (not a flat $225 for everyone).
Full evidence-graded answer
Does insurance cover Zepbound?
Most commercial insurance plans cover Zepbound with prior authorization for adults with BMI ≥30 (or ≥27 + a weight-related comorbidity). Medicare Part D excludes anti-obesity drugs by federal law, so Medicare patients pay cash unless they qualify for Lilly Cares.
Full evidence-graded answer
Is Ozempic the same as Wegovy?
Same active molecule (semaglutide), different FDA indications and maximum doses. Ozempic = type 2 diabetes, max 2 mg/week. Wegovy = chronic weight management, max 2.4 mg/week. Insurance pathways are very different.
Full evidence-graded answer
Can I still get compounded GLP-1 in 2026?
For semaglutide: no — FDA declared the shortage resolved February 21, 2025 and 503A compounding is no longer broadly permitted. For tirzepatide: shortage resolved October 2024 (re-affirmed December 2024), with a wind-down enforcement window that ended in 2025. Some clinics still market "compounded" formulations with added ingredients (B12, glycine) as personalized prescriptions; the legal status is contested.
Full evidence-graded answer
How does Wegovy compare to Saxenda?
Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.
Full evidence-graded answer

Was this page helpful?